Roivant Sciences (STU:87S) Accounts Payable & Accrued Expense : €78.14 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Roivant Sciences Accounts Payable & Accrued Expense?

Roivant Sciences's quarterly accounts payable & accrued expense declined from Sep. 2024 (€92.95 Mil) to Dec. 2024 (€85.31 Mil) and declined from Dec. 2024 (€85.31 Mil) to Mar. 2025 (€78.14 Mil).

Roivant Sciences's annual accounts payable & accrued expense declined from Mar. 2023 (€123.99 Mil) to Mar. 2024 (€85.86 Mil) and declined from Mar. 2024 (€85.86 Mil) to Mar. 2025 (€78.14 Mil).

Roivant Sciences Accounts Payable & Accrued Expense Historical Data

The historical data trend for Roivant Sciences's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences Accounts Payable & Accrued Expense Chart

Roivant Sciences Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Mar25

Accounts Payable & Accrued Expense

49.51

107.65

123.99

85.86

78.14

Roivant Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															85.86	115.11	92.95	85.31	78.14

Roivant Sciences Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Roivant Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (STU:87S) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ROIV:USA

Address

50 Broadway, 7th Floor, London, GBR, SW1H 0BD

Website

https://www.roivant.com

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Roivant Sciences Headlines

No Headlines